Neoadjuvant therapy of PD-1 inhibitor combined with TP effectively improved the MPR and LPS rates of LAHPC patients, especially in those at clinical stage IV.
Keyphrases
- locally advanced
- rectal cancer
- end stage renal disease
- neoadjuvant chemotherapy
- squamous cell carcinoma
- lymph node
- ejection fraction
- chronic kidney disease
- radiation therapy
- phase ii study
- newly diagnosed
- papillary thyroid
- inflammatory response
- peritoneal dialysis
- prognostic factors
- clinical trial
- stem cells
- lymph node metastasis
- mesenchymal stem cells
- study protocol
- smoking cessation
- replacement therapy